The use of a synthetic prostaglandin-E1 analog (misoprostol) as an adjunct to pancreatic-enzyme replacement in cystic-fibrosis
Data(s) |
1988
|
---|---|
Resumo |
Eleven cystic fibrosis children (mean age, 9.6 years) were chosen at random to participate in a study to observe the effects of concurrently stimulating gastric/duodenal bicarbonate secretion and inhibiting gastric acid secretion, using a methylated prostaglandin E1 analogue in patients with pancreatic insufficiency and taking pancreatic enzymes. Percentage fat absorption in 3-day stool collections were calculated before and after commencing therapy with misoprostol, 400 μg/day in divided doses. We found a significant reduction in fat output (14.7 ± 11.7 versus 7.5 ± 3.5 g/day, p < 0.05) in the study group as a whole and a significant reduction in steatorrhoeic level as a percentage of fat intake in all of the patients with abnormal base-line collections (23.1% versus 9.2%, p < 0.002). We conclude that misoprostol should be considered in cystic fibrosis patients with steatorrhoea as a means of improving nutrient absorption. |
Identificador | |
Publicador |
Taylor & Francis |
Relação |
DOI:10.3109/00365528809090235 Cleghorn, G.J., Shepherd, R.W., & Holt, T.L. (1988) The use of a synthetic prostaglandin-E1 analog (misoprostol) as an adjunct to pancreatic-enzyme replacement in cystic-fibrosis. Scandinavian Journal of Gastroenterology, 23(S143), pp. 142-147. |
Fonte |
Faculty of Health; Institute of Health and Biomedical Innovation |
Palavras-Chave | #Cystic fibrosis, pancreatic insufficiency, prostaglandin E1 |
Tipo |
Journal Article |